In a particular sub-group of breast cancer, i.e. the triple negative breast cancers, defined by absence of estrogen receptor, progesterone receptor and without overexpression or amplification of EGF receptor 2, the level of DNM2 overexpression was negatively correlated with positive chemotherapy outcome [41]. This evidence concerns the gene DNM2 and triple-negative breast carcinoma.